BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ConMed Corporation (CNMD) Announces Second Quarter 2012 Financial Results


7/26/2012 8:47:42 AM

UTICA, NY--(Marketwire - July 26, 2012) - CONMED Corporation (NASDAQ: CNMD)

  • Sales Increase 3.5%
  • GAAP EPS Increases 20%
  • Adjusted EPS Increases 23%

CONMED Corporation (NASDAQ: CNMD) today announced financial results for the second quarter ended June 30, 2012.

"CONMED delivered strong earnings and generated solid cash flow during the second quarter," commented Mr. Joseph J. Corasanti, President and CEO. "Earnings per share grew 20% and adjusted earnings per share increased 23% on overall sales growth of 3.5%. Single-use products continued their momentum from the first quarter, achieving overall revenue growth of 7.5%. Moreover, we continue to improve our operating and EBITDA margin metrics."

As discussed below under "Use of Non-GAAP Financial Measures," the Company presents various non-GAAP adjusted financial measures in this release. Investors should consider adjusted measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with generally accepted accounting principles ("GAAP"). Please refer to the attached reconciliation between GAAP and adjusted financial measures.

Second Quarter 2012 Financial Highlights:

  • Sales grew to $189.7 million, an increase of 3.5% (organic decline of 0.4%).

  • Single-use products comprised 81.1% of total revenues and grew 7.5%, while sales of capital products declined 10.7%.

  • Diluted earnings per share (GAAP) grew 20.0% to $0.36.

  • Adjusted diluted earnings per share grew 22.9% to $0.43.

  • Adjusted operating margin expanded 90 basis points to 10.6%.

  • GAAP operating margin was 9.0%.

  • Adjusted EBITDA margin expanded 160 basis points to 16.4%.

  • GAAP EBITDA margin operating margin was 14.8%.

  • The Board of Directors continued the cash dividend policy and declared the second quarterly dividend of $0.15 per share, which was paid on July 6, 2012.

Six Months 2012 Financial Highlights

  • Sales grew to $384.0 million, an increase of 4.7% (increase of 0.7% organic).

  • Single-use products comprised 80.3% of total revenues and grew 8.3%, while capital products declined 7.6%.

  • Diluted earnings per share (GAAP) grew 16.4% to $0.71.

  • Adjusted earnings per share grew 18.1% to $0.85.

  • Adjusted operating margin expanded 60 basis points to 10.6%.

  • GAAP operating margin was 8.9%.

  • Adjusted EBITDA margin expanded 160 basis points to 16.5%.

  • GAAP EBITDA margin was 14.8%.

International sales in the second quarter and first half of 2012 were $96.4 million and $194.6 million, respectively, slightly more than 50.0% of total sales. The recent volatility in foreign currency exchange rates was mitigated by the Company's currency hedging. Net of the hedges, foreign currency exchange rates were approximately the same in 2012 as those of 2011.

Cash provided by operating activities in the second quarter of 2012 increased from the prior year period and amounted to $25.6 million. For the six months ended June 2012, cash provided by operating activities totaled $33.3 million. As previously disclosed, cash flow in the first quarter of 2012 was affected by a contribution of $6.5 million to the Company's frozen pension plan and payment of incentive compensation.

Outlook

"CONMED has demonstrated superior earnings and cash flow in the first half of 2012 and we expect to continue these trends in the second half of the year," continued Mr. Corasanti. "Therefore, we are reiterating the previously provided full year 2012 earnings guidance of adjusted earnings per share of $1.75 - $1.85. As to the top-line, while single-use product sales continue to be strong, capital product sales in the first half of 2012 were lower than anticipated due to lingering global economic headwinds. Accordingly, the sales forecast for 2012 has been revised to $765 - $775 million from $775 - $785 million."

"For the third quarter of 2012, we anticipate sales will approximate $180 - $185 million and adjusted earnings per share are forecasted to be $0.38 - $0.42," noted Mr. Corasanti.

The sales and earnings forecasts have been developed using June 2012 currency exchange rates and take into account the currency hedges entered into by the Company. CONMED estimates that 80% of the currency exposure is hedged for 2012 at the following average annual exchange rates: Euro - $1.41, CAD - $1.00, GPB - $1.60 and AUD - $1.00.

The adjusted estimates for the second quarter and full year 2012 exclude unusual matters, such as the manufacturing restructuring costs expected to be incurred in 2012 due to the relocation of manufacturing activities from the Santa Barbara, California site to the Company's facilities in Chihuahua, Mexico and Largo, Florida. Marketing and R&D activities will remain in Santa Barbara, as previously disclosed. Additionally, the Company has announced the consolidation of the Tampere, Finland location into United States facilities. The consolidation will occur over the next twelve months and costs related to this consolidation are excluded from the estimates above.

Association with The Musculoskeletal Transplant Foundation

On January 3, 2012, CONMED became the exclusive world-wide marketing representative of MTF's sports medicine allograft tissues. In accordance with MTF's commitment to the stewardship of the donated gift, the organization maintains full responsibility for all activities related to donor suitability, quality acceptance, processing, storage, and distribution of the tissue, as well as reimbursement of service fees related to the sports medicine allografts. CONMED's team of surgical representatives serves as the educational resource to surgeons and facilities concerning the suitability of MTF allografts for ligament reconstruction, cartilage repair and meniscal transplantation, as well as for biologic solutions, including scaffolds and fixation devices. MTF will share 50% of the service revenue with CONMED for these educational activities.

Upon signing of the agreement, CONMED paid $63 million to MTF. The agreement calls for additional consideration to be paid to MTF of $84 million over the next four years contingent upon MTF providing an adequate supply of tissue. We have recorded the full amount of the consideration as a long term asset and amortize this amount ratably over the 25 year life of the agreement. Remaining contingent payments to MTF have been recorded as other liabilities. Revenues from the MTF association amounted to $7.2 million in the second quarter of 2012 and $14.7 million for the first six month of 2012.

Unusual charges

During the first half of 2012, the Company continued the on-going consolidation of certain administrative functions and the transfer of additional product lines to its Mexican manufacturing facility and began the consolidation of the Tampere facility. Also incurred were integration costs relative to the purchase of a distributor in northern Europe and litigation costs associated with a contractual dispute with a former distributor. Expenses associated with these activities, including severance and relocation costs, amounted to $1.9 million, net of tax, in the second quarter of 2012 and $4.1 million net of tax for the six months. These charges are included in the GAAP earnings per share set forth above and are excluded from the adjusted results. For the remainder of 2012, the Company presently anticipates incurring additional pre-tax restructuring costs of $5.0 - $6.0 million on projects currently in process.

Use of non-GAAP financial measures

Management has disclosed adjusted financial measurements in this press announcement that present financial information that is not in accordance with generally accepted accounting principles. These measurements are not a substitute for GAAP measurements, although Company management uses these measurements as aids in monitoring the Company's on-going financial performance from quarter-to-quarter and year-to-year on a regular basis, and for benchmarking against other medical technology companies. Adjusted net income and adjusted earnings per share measure the income of the Company excluding unusual credits or charges that are considered by management to be outside of the normal on-going operations of the Company. Management uses and presents adjusted net income and adjusted earnings per share because management believes that in order to properly understand the Company's short and long-term financial trends, the impact of unusual items should be eliminated from on-going operating activities. These adjustments for unusual items are derived from facts and circumstances that vary in frequency and impact on the Company's results of operations. Management uses adjusted net income and adjusted earnings per share to forecast and evaluate the operational performance of the Company as well as to compare results of current periods to prior periods on a consistent basis. Adjusted financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. Investors should consider adjusted measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with GAAP.

Conference call

The Company will webcast its second quarter 2012 conference call live over the Internet at 10:00 a.m. Eastern Time on Thursday, July 26, 2012. This webcast can be accessed from CONMED's web site at www.conmed.com. Replays of the call will be made available through August 5, 2012.

CONMED profile

CONMED is a medical technology company with an emphasis on surgical devices and equipment for minimally invasive procedures and patient monitoring. The Company's products serve the clinical areas of arthroscopy, powered surgical instruments, electrosurgery, cardiac monitoring disposables, endosurgery and endoscopic technologies. They are used by surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology. Headquartered in Utica, New York, the Company's 3,400 employees distribute its products worldwide from several manufacturing locations.

Forward Looking Information

This press release contains forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company's performance on a going-forward basis. The forward-looking statements in this press release involve risks and uncertainties which could cause actual results, performance or trends, to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management's expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct. In addition to general industry and economic conditions, factors that could cause actual results to differ materially from those discussed in the forward-looking statements in this press release include, but are not limited to: (i) the failure of any one or more of the assumptions stated above, to prove to be correct; (ii) the risks relating to forward-looking statements discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2011; (iii) cyclical purchasing patterns from customers, end-users and dealers; (iv) timely release of new products, and acceptance of such new products by the market; (v) the introduction of new products by competitors and other competitive responses; (vi) the possibility that any new acquisition or other transaction may require the Company to reconsider its financial assumptions and goals/targets; (vii) increasing costs for raw materials or transportation (viii) the risk of a lack of allograft tissues due to reduced donations of such tissues or due to tissues not meeting the appropriate high standards for screening and/or processing of such tissues; and/or (ix) the Company's ability to devise and execute strategies to respond to market conditions.

                                                                            
                             CONMED CORPORATION                             
                     CONSOLIDATED STATEMENTS OF INCOME                      
                  (in thousands except per share amounts)                   
                                (unaudited)                                 
                                                                            
                                  Three months ended     Six months ended   
                                       June 30,              June 30,       
                                 --------------------  -------------------- 
                                    2011       2012       2011       2012   
                                 ---------  ---------  ---------  --------- 
                                                                            
Net sales                        $ 183,236  $ 189,695  $ 366,686  $ 384,011 
                                                                            
Cost of sales                       90,795     88,761    177,775    180,692 
Cost of sales, other - Note A          986      1,202      1,740      2,676 
                                 ---------  ---------  ---------  --------- 
                                                                            
Gross profit                        91,455     99,732    187,171    200,643 
                                 ---------  ---------  ---------  --------- 
                                                                            
Selling and administrative          67,862     73,707    137,940    148,513 
Research and development             6,797      7,192     14,478     14,287 
Other expense- Note B                   98      1,775        792      3,763 
                                 ---------  ---------  ---------  --------- 
                                    74,757     82,674    153,210    166,563 
                                 ---------  ---------  ---------  --------- 
                                                                            
Income from operations              16,698     17,058     33,961     34,080 
                                                                            
Amortization of debt discount        1,113          -      2,207          - 
                                                                            
Interest expense                     1,707      1,551      3,512      2,988 
                                 ---------  ---------  ---------  --------- 
                                                                            
Income before income taxes          13,878     15,507     28,242     31,092 
                                                                            
Provision for income taxes           5,198      5,211     10,567     10,828 
                                 ---------  ---------  ---------  --------- 
                                                                            
Net income                       $   8,680  $  10,296  $  17,675  $  20,264 
                                 =========  =========  =========  ========= 
                                                                            
Per share data:                                                             
                                                                            
  Net Income                                                                
    Basic                        $     .31  $     .36  $     .62  $     .72 
    Diluted                            .30        .36        .61        .71 
                                                                            
  Weighted average common shares                                            
    Basic                           28,448     28,327     28,356     28,178 
    Diluted                         28,883     28,672     28,820     28,577 
                                                                            

Note A - Included in cost of sales, other in the three and six months ended June 30, 2011 are $1.0 million and $1.7 million, respectively, related to the consolidation of our production facilities. For the three and six months ending June 30, 2012, we incurred $1.2 million and $2.7 million, respectively, related to the consolidation of our production facilities.

Note B - Included in other expense in the three and six months ended June 30, 2011 are $0.1 million and $0.8 million, respectively, related to consolidating certain administrative functions at our Utica, New York facility. For the three and six months ending June 30, 2012, we incurred $1.2 million and $1.5 million, respectively, related to administrative consolidation expense. Also included in other expense in the three and six months ending June 30, 2012 are $0.5 million and $1.6 million, respectively, in legal costs associated with a contractual dispute with a former distributor. Included in the six months ending June 30, 2012 is $0.7 million in costs associated with the acquisition of our former distributor in the Nordic region of Europe.

                                                                            
                                                                            
                                                                            
                             CONMED CORPORATION                             
                   CONSOLIDATED CONDENSED BALANCE SHEETS                    
                               (in thousands)                               
                                (unaudited)                                 
                                   ASSETS                                   
                                                                            
                                                 December 31,    June 30,   
                                                     2011          2012     
                                                 ------------  ------------ 
Current assets:                                                             
  Cash and cash equivalents                      $     26,048  $     16,246 
  Accounts receivable, net                            135,641       136,095 
  Inventories                                         168,438       159,151 
  Deferred income taxes                                10,283        10,906 
  Other current assets                                 16,314        15,037 
                                                 ------------  ------------ 
    Total current assets                              356,724       337,435 
                                                                            
Property, plant and equipment, net                    139,187       140,844 
Deferred income taxes                                   2,389         2,443 
Goodwill                                              234,815       234,839 
Other intangible assets, net                          195,531       191,741 
Other assets                                            6,948       153,929 
                                                 ------------  ------------ 
    Total assets                                 $    935,594  $  1,061,231 
                                                 ============  ============ 
                                                                            
LIABILITIES AND SHAREHOLDERS' EQUITY                                        
                                                                            
Current liabilities:                                                        
  Current portion of long-term debt              $     54,557  $     22,534 
  Other current liabilities                            76,627       112,713 
                                                 ------------  ------------ 
    Total current liabilities                         131,184       135,247 
                                                                            
Long-term debt                                         88,952       145,437 
Deferred income taxes                                  92,785        99,417 
Other long-term liabilities                            49,602        87,747 
                                                 ------------  ------------ 
    Total liabilities                                 362,523       467,848 
                                                 ------------  ------------ 
                                                                            
Shareholders' equity:                                                       
  Capital accounts                                    244,980       255,044 
  Retained earnings                                   354,439       366,219 
  Accumulated other comprehensive loss                (26,348)      (27,880)
                                                 ------------  ------------ 
    Total shareholders' equity                        573,071       593,383 
                                                 ------------  ------------ 
                                                                            
    Total liabilities and shareholders' equity   $    935,594  $  1,061,231 
                                                 ============  ============ 
                                                                            
                                                                            
                                                                            
                             CONMED CORPORATION                             
              CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS               
                               (in thousands)                               
                                (unaudited)                                 
                                                                            
                                                      Six months ended      
                                                          June 30,          
                                                 -------------------------- 
                                                     2011          2012     
                                                 ------------  ------------ 
Cash flows from operating activities:                                       
  Net income                                     $     17,675  $     20,264 
  Adjustments to reconcile net income to net                                
   cash provided by operating activities:                                   
    Depreciation and amortization                      21,047        23,064 
    Stock-based compensation expense                    2,232         2,574 
    Deferred income taxes                               8,981         6,091 
    Increase (decrease) in cash flows from                                  
     changes in assets and liabilities:                                     
      Accounts receivable                              (4,541)       (1,027)
      Inventories                                          78         3,078 
      Accounts payable                                  2,309         1,345 
      Income taxes payable                                143        (4,589)
      Accrued compensation and benefits                (5,684)       (6,730)
      Other assets                                     (2,226)       (1,779)
      Other liabilities                                   209        (9,014)
                                                 ------------  ------------ 
  Net cash provided by operating activities            40,223        33,277 
                                                 ------------  ------------ 
                                                                            
Cash flows from investing activities:                                       
      Purchases of property, plant, and                                     
       equipment                                       (8,576)      (11,596)
      Payments related to business acquisitions                             
       and distribution agreement                         (72)      (64,116)
                                                 ------------  ------------ 
  Net cash used in investing activities                (8,648)      (75,712)
                                                 ------------  ------------ 
                                                                            
Cash flows from financing activities:                                       
      Payments on debt                                (23,113)      (32,538)
      Proceeds from debt                                    -        57,000 
      Dividend payments from common stock                   -        (4,328)
      Net proceeds from common stock issued                                 
       under employee plans                             5,495         7,868 
      Other, net                                       (3,148)        4,925 
                                                 ------------  ------------ 
  Net cash provided by (used in) financing                                  
   activities                                         (20,766)       32,927 
                                                 ------------  ------------ 
                                                                            
Effect of exchange rate change on cash and cash                             
 equivalents                                            1,105          (294)
                                                 ------------  ------------ 
                                                                            
Net increase (decrease) in cash and cash                                    
 equivalents                                           11,914        (9,802)
                                                                            
Cash and cash equivalents at beginning of period       12,417        26,048 
                                                 ------------  ------------ 
                                                                            
Cash and cash equivalents at end of period       $     24,331  $     16,246 
                                                 ============  ============ 
                                                                            
                                                                            
                                                                            
                             CONMED CORPORATION                             
        RECONCILIATION OF REPORTED NET INCOME TO NON-GAAP NET INCOME        
           BEFORE UNUSUAL ITEMS AND AMORTIZATION OF DEBT DISCOUNT           
                 Three Months Ended June 30, 2011 and 2012                  
                  (in thousands except per share amounts)                   
                                (unaudited)                                 
                                                                            
                                                          2011       2012   
                                                       ---------  --------- 
                                                                            
Reported net income                                    $   8,680  $  10,296 
                                                       ---------  --------- 
                                                                            
Facility consolidation costs included in cost of sales       986      1,202 
                                                       ---------  --------- 
                                                                            
Administrative consolidation costs included in other                        
 expense                                                      98      1,231 
                                                                            
Legal costs included in other expense                          -        544 
                                                       ---------  --------- 
                                                                            
  Total other expense                                         98      1,775 
                                                       ---------  --------- 
                                                                            
Amortization of debt discount                              1,113          - 
                                                       ---------  --------- 
                                                                            
Unusual expense before income taxes                        2,197      2,977 
                                                                            
Provision (benefit) for income taxes on unusual                             
 expenses                                                   (801)    (1,072)
                                                       ---------  --------- 
                                                                            
Net income before unusual items and amortization of                         
 debt discount                                         $  10,076  $  12,201 
                                                       =========  ========= 
                                                                            
Per share data:                                                             
                                                                            
Reported net income                                                         
  Basic                                                $    0.31  $    0.36 
  Diluted                                                   0.30       0.36 
                                                                            
Net income before unusual items and amortization of                         
 debt discount                                                              
  Basic                                                $    0.35  $    0.43 
  Diluted                                                   0.35       0.43 
                                                                            

Management has provided the above reconciliation of net income before unusual items and amortization of debt discount as an additional measure that investors can use to compare operating performance between reporting periods. Management believes this reconciliation provides a useful presentation of operating performance as discussed in the section "Use of Non-GAAP Financial Measures" above. We have included the amortization of debt discount in our analysis in order to facilitate comparison with the non-GAAP earnings guidance provided in the "Outlook" section of this and previous releases which exclude such expense.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES